行情

PSTI

PSTI

Pluristem
NASDAQ

实时行情|Nasdaq Last Sale

3.400
+0.050
+1.49%
已收盘, 16:00 11/11 EST
开盘
3.320
昨收
3.350
最高
3.400
最低
3.250
成交量
3.78万
成交额
--
52周最高
11.90
52周最低
3.210
市值
5,239.55万
市盈率(TTM)
-0.1157
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

PSTI 新闻

  • The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut
  • Benzinga.3天前
  • RESTORE Consortium to Host the 1st Advanced Therapies Science Meeting, Aiming to Translate Promising Research into a Game Changer in Healthcare
  • GlobeNewswire.11/04 12:00
  • Pluristem Therapeutics Sees Hammer Chart Pattern: Time to Buy?
  • Zacks.10/28 16:16
  • Watching Pluristem Shares Following Tweet From Patent Grants Highlighting WIPO PatentScope Application For 'use of specialized vessels for formulating and dispensing pharmaceutical formulations'
  • Benzinga.10/24 13:52

更多

所属板块

生物技术和医学研究
-0.51%
制药与医学研究
-0.43%

热门股票

名称
价格
涨跌幅

PSTI 简况

Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.
展开

Webull提供Pluristem Therapeutics Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。